An independent clinical trial of Ancient + Brave's True Skin Alchemy supplement found that 100% of enrolled perimenopausal women showed measurable improvements in skin hydration, elasticity, and barrier function — a clean sweep across all three primary endpoints that positions the brand squarely in the fast-growing femtech-meets-nutraceuticals space.
The full responder rate is a notable clinical result. In most skin-health supplement trials, even well-powered studies report meaningful non-responder fractions, so a 100% improvement rate — however modest the individual gains — signals strong formulation efficacy or a particularly receptive population. Because perimenopausal estrogen decline directly compromises dermal collagen synthesis, ceramide production, and transepidermal water loss, this demographic represents a high-need segment that the broader beauty-from-within category has increasingly targeted.
The Formulation Angle
True Skin Alchemy is positioned as a multi-ingredient finished formulation rather than a single-actives play. The perimenopause-specific positioning aligns with a broader industry shift toward life-stage nutrition, where operators and contract manufacturers are moving beyond generic "skin, hair, and nails" SKUs toward condition-specific blends backed by clinical endpoints. Ingredients commonly found in this category — including hydrolyzed marine or bovine collagen peptides, hyaluronic acid, ceramides, vitamin C as a cofactor for collagen cross-linking, and adaptogenic botanicals — are frequently combined to address the multi-factorial skin changes that accompany hormonal transition. Ancient + Brave has not disclosed the full ingredient deck or dose per serving in the release, limiting independent assessment of the bioavailability profile.
Market Context
The global nutricosmetics market was valued at roughly $7 billion in 2024 and is projected to grow at a compound annual rate above 8% through the end of the decade, driven in large part by ingestible collagen and the expanding menopause-wellness segment. Perimenopause-focused products have attracted significant retail and direct-to-consumer investment over the past 18 months, with brands citing the estimated 1 billion women globally who will be in perimenopause or postmenopause by 2025 as an underserved addressable market. For formulators and white-label manufacturers, the segment offers strong margin potential and a consumer base that indexes high for clinical substantiation and premium price tolerance.
For operators evaluating the competitive landscape, the independent trial designation matters. Third-party, independently conducted studies carry more regulatory weight than manufacturer-sponsored research when substantiating structure-function claims under FTC and FDA guidelines — a distinction increasingly scrutinized as beauty-supplement marketing faces tighter enforcement attention. Brands pairing clinical evidence with transparent dosing and standardized-extract disclosure are better positioned to withstand retailer and regulatory due diligence.
Ancient + Brave has built its positioning around premium, clean-label formulations in the collagen and functional nutrition space. The True Skin Alchemy trial result adds a quantifiable clinical credential to what has historically been a category driven by consumer testimonials and in-vitro ingredient data. How the brand leverages this endpoint data in retail, practitioner, and direct-to-consumer channels will determine how much commercial lift the trial ultimately delivers.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
